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ORIGINAL ARTICLE
The novel Syk inhibitor R406 reveals mechanistic differences in
the initiation of GPVI and CLEC-2 signaling in platelets1
J . C . SPALTON,* J . MOR I ,* A . Y . POLL ITT ,* C . E . HUGHES ,* J . A . EBLE and S . P . WATSON*
*Centre for Cardiovascular Sciences, Institute for Biomedical Research, The College of Medical and Dental Sciences, University of Birmingham,
Edgbaston, Birmingham, UK; and Center for Molecular Medicine, Frankfurt University Hospital, Frankfurt am Main, Germany
To cite this article: Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP. The novel Syk inhibitor R406 reveals mechanistic differences in
the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost 2009; DOI:10.1111/j.1538-7836.2009.03451.x.
Summary. Background: Syk is a key mediator of signaling
pathways downstream of several platelet surface receptors
including GPVI/FcRc collagen receptor, the C-type lectin
receptor CLEC-2, and integrin aIIbb3. A recent study
identiﬁed the novel small molecule R406 as a selective
inhibitor of Syk. Objectives: The present study evaluates the
role of Syk in human platelets using the novel inhibitor R406.
Methods: Agonist-induced GPVI and CLEC-2 signaling were
assessed using aggregometry, immunoprecipitation and wes-
tern blotting to determine the eﬀects of R406 on platelet
activation. Results: We demonstrate R406 to be a powerful
inhibitor of Syk in human platelets. R406 abrogated shape
change and aggregation induced by activation of GPVI and
CLEC-2, and reduced platelet spreading on ﬁbrinogen. The
inhibitory eﬀect of R406 was associated with inhibition of
tyrosine phosphorylation of signaling proteins that lay
downstream of Syk for all three receptors, including PLCc2.
Strikingly, R406 markedly inhibited tyrosine phosphorylation
of CLEC-2 and Syk downstream of CLEC-2 activation,
whereas phosphorylation of Syk downstream of GPVI and
integrin aIIbb3 was unaﬀected. Conclusions: The inhibitory
eﬀect of R406 provides direct evidence of a role for Syk in
GPVI, CLEC-2 and integrin aIIbb3 signaling in human
platelets. Further, the results demonstrate a critical role for
Syk in mediating tyrosine phosphorylation of CLEC-2,
suggesting a novel model in which both Src and Syk kinases
mediate tyrosine phosphorylation of the C-type lectin receptor
leading to platelet activation.
Keywords: CLEC-2, GPVI, integrin aIIbb3, platelets, Syk.
Introduction
Spleen tyrosine kinase (Syk) and f-associated protein of
70 kDa (Zap-70) are the only two members of the Syk family
of non-receptor tyrosine kinases, which is characterised by two
N-terminal SH2 domains and a C-terminal catalytic domain.
Both members are regulated by binding to two phosphorylated
tyrosines in a sequence known as an immunoreceptor tyrosine-
based activation motif (ITAM), which has two YXXL groups,
separated by 6–8 amino acids for Zap-70, or 6–12 amino acids
for Syk. Zap-70 is expressed in T cells and natural killer cells,
whereas Syk is expressed in most cells in the hematopoietic
lineage [1]. Studies using Syk-deﬁcient mice have demonstrated
a pivotal role for the kinase in signaling downstream of ITAM
receptors, as illustrated by its role in activation of platelets by
the collagen receptor complex, GPVI/FcR c-chain (FcRc),
and in the mast cell by FceRI [2]. Syk has also been shown to
play a key role in activation of mouse platelets by integrins
a2b1 and aIIbb3, GPIb-IX-V, and the C-type lectin receptor
CLEC-2 [3–5].
The involvement of Syk in immunoreceptor signaling has
been studied extensively. On immunoreceptor activation, Src
family kinases (SFKs) phosphorylate two tyrosine residues
within the consensus ITAM, facilitating recruitment of Syk to
the plasmamembrane through its tandem SH2 domains [6]. On
relocalization, Syk undergoes both autophosphorylation and
phosphorylation by SFKs, leading to its activation, interaction
with adaptor and effector proteins, and tyrosine phosphory-
lation of downstream substrates, including PLCc2, leading to
cell activation [7,8]. In contrast, the mechanism of activation of
Syk by integrin aIIbb3, which lacks an ITAM, is controversial
[9]. It was originally proposed that integrin aIIbb3 signaling
proceeds independently of receptor tyrosine phosphorylation
[9,10], but a subsequent study provided evidence that the
phosphotyrosine-binding capacity of Syk is required for
activation by integrins, possibly via an unidentiﬁed ITAM-
containing protein [11]. Indeed, it has recently been shown that
the low afﬁnity Fc receptor, FccRIIA, couples integrin aIIbb3
to downstream signaling events in human platelets [12]. It thus
seems that aIIbb3 signals through both ITAM-dependent and
ITAM-independent regulation of Syk.
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CLEC-2 signals through a similar pathway to that of
immunoreceptors, including a critical role for sequential
activation of SFKs and Syk, and phosphorylation of common
downstream proteins including PLCc2 [13]. However, in
contrast to immunoreceptors, the C-type lectin receptor
contains a single cytoplasmic YXXL sequence, which we have
shown to be essential for activation [14]. Studies using mouse
models and cell lines deﬁcient in key signaling proteins have
demonstrated that CLEC-2 signaling can be further distin-
guished from that of the GPVI-FcRc pathway through a
partial dependence on the adapter SLP-76 [13,14].
There is considerable interest in the role of Syk in platelets
in view of its potential as an anti-thrombotic target.
Investigation into the role of Syk, however, has been
hampered by the perinatal lethality of homozygous Syk-
deﬁcient mice [15] and the absence of a truly speciﬁc
inhibitor to verify its function in human platelets. For
example, piceatannol has been used extensively as a Syk
inhibitor, but a study comparing the effects of this inhibitor
with Syk-deﬁcient mouse platelets showed differences in
functional responses, suggesting that piceatannol has off-
target effects, including inhibition of SFKs [16].
A novel small molecule inhibitor, R406, was recently
identiﬁed and shown to inhibit Syk kinase activity both in
vitro and in vivo in an ATP-competitive manner [17]. The
availability of R406 enables testing of the role for Syk in
mediating activation of human platelets. In the present study,
we demonstrate that R406 is a powerful and speciﬁc inhibitor
of Syk and that the tyrosine kinase plays a critical but
differential role in the activation of human platelets by GPVI,
CLEC-2 and integrin aIIbb3.
Experimental procedures
Reagents
Rhodocytin and CRP were obtained as previously described
[18–20]. R406 was a gift from Dr David Simmons, Cellzome
Ltd (Cambridge, UK). Phospho-Syk antibodies were from
NEB (Hertfordshire, UK). GST-Iga was expressed as a GST
fusion protein and donated byDrMike Tomlinson (University
of Birmingham, Birmingham, UK). All other reagents were
from Sigma Ltd (Poole, UK) or previously published sources
[5,8,13].
Platelet preparation and functional studies
Washed platelets (WP) were prepared as previously described
[3,14] and treated with inhibitor for 60 s prior to stimulation
with agonists. Aggregation was monitored by light transmis-
sion using a Born aggregometer (Chronolog, Havertown, PA)
[14]. Spreading on ﬁbrinogen was performed as previously
described [5]. Images were captured using differential interfer-
ence contrast (DIC) microscopy and ﬁve ﬁelds per image
analysed using IMAGE J software2 .
Western blotting
WP were pretreated with 9 lM integrilin to block aggregation,
and stimulations were carried out at 37 C with stirring.
Immunoprecipitation and western blotting were carried out as
previously described [13].
In vitro kinase assay
Syk was immunoprecipitated from platelet lysates as above,
resuspended in 40 lL kinase buffer (50 mM MOPS, 150 mM
NaCl, 5 mM MnCl2, 5 mM MgCl2), containing 5 lg GST-Iga,
1 mM DTT and 35 nM ATP, and incubated for 30 s at 37 C.
Where stated, samples were pretreated with inhibitor for 1 min.
The assay was stopped by the addition of SDS sample buffer,
and samples analysed by western blotting.
Statistical analysis
Results are shown as mean ± SE mean of three experiments.
Statistical analysis was determined by Students t-test.
Results
R406 inhibits GPVI signaling
We initially examined the effect of R406 on aggregation of
human platelets downstream of GPVI activation. Shape
change and aggregation induced by collagen related peptide
(CRP) (3 lg/mL), collagen (1 lg/mL) and convulxin (1 lg/
mL) were greatly reduced in the presence of 0.1–0.3 lM R406
and abrogated at 1 lM R406 (Fig. 1A,B, and not shown). In
contrast, R406 (1 lM) had a minor effect on aggregation
A B C D
Fig. 1.3 GPVI-induced aggregation is inhibited by R406.Washed platelets pretreated with DMSO, R406 or PP2 for 60 s were stimulated with (A) 3 lg/mL
CRP, (B) 1 lg/mL collagen, or (C) 0.03 U/mL thrombin. (D) Platelet-rich plasma was pretreated with 2 lM R406 prior to stimulation with 3 lM ADP.
Aggregation was determined by change in light transmission. Arrows mark addition of agonist. Data are representative of three independent experiments.
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induced by a low concentration of the G protein-coupled
receptor agonist, thrombin (0.03 U/mL), but had no effect on
the response to ADP (3 lM) (Fig. 1C,D). In the latter study, a
slightly higher concentration of R406 was used to overcome
protein binding in the plasma as monitored by inhibition of the
response to CRP (not shown). The SFK inhibitor PP2 (20 lM)
had a slightly greater inhibitory effect against thrombin in
washed platelets relative to that of R406 (Fig. 1C).
Having established that R406 has a powerful and potent
inhibitory effect on aggregation induced through the GPVI/
FcRc complex, we examined the underlying signaling events.
R406 (1 lM) inhibited tyrosine phosphorylation of several
protein bands in platelets stimulated by collagen, convulxin or
CRP, whilst having a negligible effect on others (Fig. 2A,B).
R406 had a more powerful inhibitory effect against low
concentrations of all three agonists, with partial recovery
observed in response to higher concentrations [Fig. 2A(i) and
not shown], most likely due to incomplete blockade of Syk. The
reduction of some but not all bands byR406 is in stark contrast
to the complete abolition of tyrosine phosphorylation to all
three agonists in the presence of the SFK inhibitor, PP2, as
illustrated forCRP inFig. 2(B), and in linewithprevious studies
[21–23]. The difference in the pattern of inhibition conﬁrms that
over the concentration range of 0.1–1 lM, R406 is selective for
SykoverSFKs.A10-foldhigher concentrationofR406 induced
a similar pattern of inhibition of tyrosine phosphorylation to
PP2, demonstrating loss of selectivity to Syk (data not shown).
The reduction in tyrosine phosphorylation was investigated
further by immunoprecipitation of signaling proteins combined
with western blotting. R406 (1 lM) markedly inhibited tyrosine
phosphorylation of LAT, SLP-76 and PLCc2 induced by
collagen, convulxin and CRP (Fig. 2 and not shown), consis-
tent with previous results in Syk-deﬁcient mice. In contrast,
tyrosine phosphorylation of FcRc and Syk by the three
agonists was not signiﬁcantly altered, conﬁrming that SFK
activity is not affected (Fig. 2). To investigate phosphorylation
of Syk in further detail, we used phospho-speciﬁc antibodies
against residues within the linker region (Y352) and kinase
domain (Y525/526) of Syk. Phosphorylation of these residues
increased in a concentration-dependent manner and was not
altered in the presence of R406 (Fig. 2A).
An in vitro kinase assay was performed on Syk immuno-
precipitates to further investigate the speciﬁcity of R406 for
Syk. Syk underwent autophosphorylation and stimulated
tyrosine phosphorylation of Iga following immunopreciptia-
tion from non-stimulated platelets. Phosphorylation was
inhibited by direct addition of R406 but not PP2 to the kinase
assay (Fig. 3A). In contrast, stimulation of platelets by CRP
induced a marked increase in Syk autophosphorylation and
Iga phosphorylation, neither of which was altered by pretreat-
ment of intact platelets with R406 (Fig. 3B). This is consistent
with the above observation that tyrosine phosphorylation of
Syk is not altered in CRP-stimulated platelets in the presence of
R406, assuming removal of the kinase inhibitor during
B (i)
(ii)
A (i)
(ii)
Fig. 2.4 R406 reduces tyrosine phosphorylation downstream of GPVI. Platelets pretreated with 1 lM R406, 20 lM PP2 or DMSO for 1 min were
stimulated with collagen, convulxin or CRP (3 lg/mL) for 90 s. Whole cell lysates [A(i), B(i)] and immunoprecipitates [A(ii), B(ii)] were immunoblotted as
stated. Data are representative of three independent experiments.
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preparation of the lysates. The above results demonstrate that
R406 is a selective inhibitor of Syk and conﬁrm a critical role
for the kinase in mediating tyrosine phosphorylation of LAT,
SLP-76 and PLCc2, and platelet aggregation induced byGPVI
agonists.
R406 inhibits CLEC-2 signaling
Syk has been shown to play a critical role in activation of
mouse platelets induced by CLEC-2 using Syk-deﬁcient mice
[12]. In the present study, a role for Syk in mediating
aggregation of human platelets in response to the snake venom
toxin, rhodocytin, or an antibody to CLEC-2, has been shown
using R406 (Fig. 4A). Signiﬁcantly, the CLEC-2 antibody
activates human platelets independent of the low afﬁnity
immune receptor, FccRIIA [14]. Strikingly, and in marked
contrast to results for GPVI, R406 (1 lM) dramatically
inhibited the increase in tyrosine phosphorylation of all
proteins in whole cell lysates induced by intermediate and high
concentrations of rhodocytin (Fig. 4B) or by the CLEC-2
antibody (Fig. 4C). This was associated with inhibition of
tyrosine phosphorylation of CLEC-2 and Syk, as well as the
downstream proteins LAT, SLP-76 and PLCc2 (Fig. 4B). The
observation that CLEC-2 runs as a doublet is consistent with
the ﬁndings of Suzuki-Inoue et al. [13], who identiﬁed that the
pair of protein bands represent differentially N-glycosylated
forms of CLEC-2. Inhibition of tyrosine phosphorylation of
Syk was conﬁrmed using phospho-speciﬁc antibodies to Y352
and Y525/526 following stimulation by R406 (Fig. 4B).
Inhibition of CLEC-2 phosphorylation and downstream
phosphorylation events was also observed in the presence of
the SFK inhibitor PP2, in addition to the inhibition of both
rhodocytin- and CLEC-2 antibody-induced aggregation ([24]
and not shown). These data conﬁrm that SFKs and Syk are key
mediators of platelet activation by CLEC-2, but identify an
unexpected role for Syk in mediating tyrosine phosphorylation
of the C-type lectin receptor.
Syk is required for lamellipodia formation on fibrinogen
The effects of R406 were further investigated on adhesion and
spreading of platelets on ﬁbrinogen. Human platelets readily
adhere to ﬁbrinogen and undergo spreading characterized by
sequential formation of ﬁlopodia and lamellipodia (Fig. 5).
There was a marked inhibition of spreading on ﬁbrinogen in
the presence of R406, with only a small proportion of platelets
generating ﬁlopodia, whereas the level of adhesion was not
altered (Fig. 5A). Similar observations were made when
platelets were treated with the SFK inhibitor PP2 (not shown),
consistent with previous observations [4,25]. However, in
contrast to the complete inhibition of tyrosine phosphorylation
that is seen in the presence of the SFK inhibitor PP2 (20 lM),
R406 (1 lM) caused a reduction in tyrosine phosphorylation of
only a small subset of proteins, including a band of 150 kDa
that co-migrates with PLCc2 (Fig. 5B). Analysis of tyrosine
phosphorylation of PLCc2 following immunoprecipitation
conﬁrmed inhibition by both PP2 and R406. On the other
hand, tyrosine phosphorylation of Syk was partially inhibited
by R406 but abolished by PP2, a result that was conﬁrmed
using phospho-speciﬁc antibodies to Syk (Fig. 5B). These
observations are consistent with previous studies in mouse
platelets, and demonstrate a critical role for Src and Syk
kinases in mediating tyrosine phosphorylation of PLCc2 and
spreading of human platelets on ﬁbrinogen.
Discussion
The present ﬁndings demonstrate R406 to be a powerful and
speciﬁc inhibitor of Syk in human platelets and enabled
veriﬁcation of a role for Syk in mediating activation of human
platelets through GPVI, CLEC-2 and integrin aIIbb3, consis-
tent with previous studies in Syk-deﬁcient mouse platelets.
Strikingly, the present study further reveals an unexpected role
for Syk in mediating tyrosine phosphorylation of CLEC-2,
A
B
Fig. 3.5 Inhibition of Syk by R406 in an in vitro kinase assay. The ability of
Syk immunoprecipitates to phosphorylate GST-Igawas determined by an
in vitro kinase assay and samples were immunoblotted as stated. (A) 1 lM
R406 or 20 lM PP2 was added directly to the kinase assay. (B) Platelets
pretreated with 1 lM R406 or 20 lM PP2 for 60 s were stimulated with
1 lg/mL CRP for 90 s prior to the kinase assay. Data are from one
experiment that is representative of four similar experiments.
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thereby demonstrating a fundamental difference in the mech-
anism of signaling by the C-type lectin receptor in comparison
with GPVI and integrin aIIbb3.
The pivotal role of Syk in mediating signaling events
downstream of GPVI/FcRc is illustrated in functional studies.
Shape change and aggregation induced by the GPVI-speciﬁc
agonist CRP were completely abrogated by 1 lMR406, as was
the case for a low concentration of the physiological agonist
collagen. There was, however, a limited recovery in response to
a 10-fold higher concentration (10 lg/mL) of collagen but not
to CRP (Supplementary data, Fig. S1), which could reﬂect
Syk-independent signaling through integrin a2b1 [26],and
possibly activation of a third, unidentiﬁed, receptor [27]. In
contrast, Braselmann et al. [17] reported no effect of R406
when given orally on collagen-induced aggregation in human
subjects, although it is unclear whyR406 is not effective against
collagen when given in this way. We have also shown that Syk
inhibition does not affect adhesion to ﬁbrinogen but blocks
platelet spreading through the inhibition of lamellipodia
formation. This is consistent with observations in Syk-deﬁcient
mouse platelets that ﬁrst demonstrated a role for Syk in
mediating platelet spreading downstream of integrin aIIbb3 [4]
and the recent demonstration of a role for FccRIIA in
mediating signaling by the integrin [12].
R406 had a weak inhibitory effect on platelet aggregation
induced by thrombin, which signals through the Gq-coupled
family of G proteins. The inhibitory effect of R406 was slightly
smaller than that of the SFK inhibitor, PP2, suggesting that
SFKs may contribute at least partly to thrombin-induced
aggregation through activation of Syk. On the other hand,
R406 had no effect on the response to ADP, which signals
through a synergistic interaction between theGi-coupled P2Y12
receptor and Gq-coupled P2Y1 receptor. We have previously
reported that aggregation induced by thrombin in mouse
platelets is independent of SFK and Syk, suggesting a species
difference [5]. In this context, it is noteworthy that the major
receptor for thrombin in mouse platelets is PAR-4, whereas in
humans it is PAR-1.
A B
C
Fig. 4.6 R406 inhibits CLEC-2 signaling. Platelets pretreated with R406 or DMSO for 1 min were stimulated with 100 nM rhodocytin (rhod) or 20 lg/mL
CLEC-2 antibody (Ab). (A) Aggregation was determined by change in light transmission. Whole cell lysates [B(i), C] and immunoprecipitates [B(ii), C]
were immunoblotted as stated. Data are representative of three independent experiments.
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Phospho-speciﬁc antibodies have proved to be a useful tool
in measuring the tyrosine phosphorylation of Syk at speciﬁc
residues, and have provided new information into the mech-
anism of Syk activation in human platelets. It has been shown
that upon B cell receptor activation, the SFK Lyn phospho-
rylates Syk at position Y352 [28], thereby leading to phos-
phorylation at further sites, including autophosphorylation of
tyrosines 525 and 526 within the kinase domain [29,30].
Tyrosine phosphorylation at Y525/526 has been used in several
studies as a marker for Syk activity as it ﬁts with the generic
kinase regulatory mechanism in which activation loop phos-
phorylation causes a conformational change to an active state
[31]. However, there has been much discussion regarding the
mechanism of activation loop phosphorylation, with the
proposal that the relative contribution of SFK and autophos-
phorylation varies with cell type [30,32]. The present study has
resolved this issue in human platelets by reporting both a
normal level of Syk phosphorylation as measured using
phospho-speciﬁc antibodies in the presence of R406 and full
kinase activity upon washout of R406. This suggests that Syk is
phosphorylated downstream of Src kinases rather than
through autophosphorylation. Consistent with this, R406 but
not PP2, inhibited Syk autophosphorylation and phosphory-
lation of an exogenous substrate in an in vitro assay, in
conﬁrmation of the ﬁndings of Cha et al. [33], whereas R406
had no effect on Syk activation in CRP-stimulated platelets
A (i)
(ii) (iii)
B
Fig. 5.7 R406 blocks lamellipodia formation on fibrinogen. (A) Platelets were treated as indicated before plating on fibrinogen-coated dishes. Fixed
adherent platelets were imaged [A(i)] and analysed for mean platelet area ± SE [A(ii)] and adhesion ± SE [A(iii)]. (B) Whole cell lysates and
immunoprecipitates were immunoblotted with stated antibodies; ***P < 0.001. Data are representative of three independent experiments.
Fig. 6.8 Model of CLEC-2 activation. Src family kinase (SFK) phosphorylation of CLEC-2 allows recruitment of Syk via one of its SH2 domains (i). The
opposing orientation of the kinase domain enables Syk to phosphorylate the second CLEC-2 receptor in the dimer, leading to a rearrangement in binding
that allows cross-linking of two CLEC-2 receptors via its SH2 domains (ii). Syk is fully activated by SFK-mediated phosphorylation, and possibly
autophosphorylation, initiating downstream signaling (iii).
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pretreated with R406. This illustrates that Syk undergoes
phosphorylation in intact platelets in the presence of Syk
inhibition, and provides direct evidence of the inhibitory effect
of R406 on Syk.
An unexpected ﬁnding from the present study is the critical
role that Syk plays in mediating tyrosine phosphorylation of
CLEC-2 induced by either rhodocytin or the CLEC-2
antibody. This is in marked contrast to stimulation of platelets
through GPVI by CRP, collagen and the snake venom toxin,
convulxin, in which phosphorylation of the FcRc is minimally
altered in the presence of R406. Thus, the results suggest that
both SFKs and Syk play a role in mediating tyrosine
phosphorylation of CLEC-2. Although the GPVI/FcRc and
CLEC-2 signaling pathways share common elements, CLEC-2
has a single YXXLmotif in its cytoplasmic tail, compared with
the tandem YXXL motif in FcRc. Even so, point mutations
that destroy phosphotyrosine binding in either of the two SH2
domains in Syk abrogate signaling by CLEC-2 [14], suggesting
that Syk must crosslink phosphorylated YXXL motifs in two
CLEC-2 receptors to mediate activation, consistent with the
observation that rhodocytin causes clustering of the CLEC-2
receptor [34]. Together, these observations lay the foundation
for the proposal of a novel pathway through which CLEC-2
initiates signaling, which is distinct from that used by GPVI.
In the model shown in Fig. 6, we propose that both SFKs
and Syk directly mediate tyrosine phosphorylation of CLEC-2.
In this model, receptor dimerisation leads to Src-dependent
tyrosine phosphorylation of the YXXL motif of CLEC-2 and
transient recruitment of Syk, via either of its SH2 domains, to
the phosphorylated tyrosine [Fig. 6(i)]. The crystal structure
shows that the tyrosine kinase domain of Syk is positioned in
the opposite direction to the tandem SH2 domains [35]. Thus,
binding of Syk brings its kinase domain into contact with the
YXXL sequence in the second CLEC-2 receptor and allows
subsequent phosphorylation of this motif [Fig. 6(ii)]. In turn,
this leads to a rearrangement of binding such that Syk is able to
crosslink two CLEC-2 receptors via its tandem SH2 domains
[Fig. 6(iii)]. In this position, Syk is then activated by SFK
phosphorylation at position 352, and possibly also at positions
525 and 526, although the latter could be mediated by
autophosphorylation. Activation of Syk in this way initiates
a series of downstream events leading to tyrosine phosphor-
ylation and activation of PLCc2. In this model, the initial
transient phosphorylation of CLEC-2 by SFKs may be subject
to rapid dephosphorylation, whilst binding of Syk would
prevent protein tyrosine phosphatases from accessing and
dephosphorylating the ITAM. Alternative models in which
receptor phosphorylation is mediated solely by engagement of
either SFKs or Syk would seem less likely because inhibition of
either kinase type results in abrogation of receptor phosphor-
ylation. Indeed, the interaction between the tyrosine phospha-
tase SHP2 and the PDGF receptor provides a precedent for the
model shown in Fig. 5, as the tandem SH2 domains of SHP2
are believed to bridge PDGF receptor dimers by binding
equivalent recognition sites on each monomer [36]. Further
studies will enable more detailed analysis of the events involved
in CLEC-2 receptor activation and downstream signaling, and
will allow this model to be developed.
In summary, we have used the novel inhibitor R406 to
demonstrate a role for Syk in GPVI-, CLEC-2- and aIIbb3-
signaling in human platelets. Further, we have identiﬁed a
mechanistic difference between the CLEC-2 and GPVI signal-
ing pathways that has led us to propose a model of CLEC-2
signaling in which SFKs and Syk combine together to directly
phosphorylate the C-type lectin receptor.
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